Figure 5.
Change from baseline in homeostasis model of assessment–insulin resistance (HOMA-IR) in the safety population through week 144. The change from baseline was calculated using mixed-model repeated measures adjusting for treatment, visit, baseline third agent class, CD4+ cell count (continuous), age (continuous), sex, race, body mass index (continuous), presence of hypertension, loge-transformed baseline HOMA-IR (continuous), treatment-by-visit interaction, and baseline value-by-visit interaction, with visit as the repeated factor. Abbreviations: CI, confidence interval; DTG/3TC, dolutegravir/lamivudine; TAF, tenofovir alafenamide.